NanoVation Therapeutics Announces Multi-Target Partnership …
VANCOUVER, British Columbia, September 18, 2024--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today...
NanoVation Therapeutics Announces Multi-Target Partnership …
Sep 18, 2024 · VANCOUVER, British Columbia-- (BUSINESS WIRE)-- NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced...
NTx partnership with Novo Nordisk - NanoVation Therapeutics
Sep 18, 2024 · The partnership combines NanoVation Therapeutics’ proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian …
Sep 18, 2024 · Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE: NVO) to advance the development of novel genetic medicines targeting...
NTx News & Events - NanoVation Therapeutics
NanoVation Therapeutics announces multi-target partnership with Novo Nordisk to develop genetic medicines targeting cardiometabolic and rare diseases. September 18, 2024. NTx is eligible to receive up to ~US$600M and royalties in multi-year deal aimed at enabling nucleic acid delivery to cells outside of the liver.
Vancouver Biotech Startup NanoVation Therapeutics Announces …
Sep 23, 2024 · Vancouver-based biotech startup NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.
Novo inks $600M NanoVation deal to study genetic drugs ex-liver
Sep 18, 2024 · Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting...
诺和诺德达成6亿美元合作，布局肝外LNP递送技术_腾讯新闻
Sep 19, 2024 · NanoVation Therapeutics今日宣布与诺和诺德（Novo Nordisk）达成一项多年研发合作伙伴关系，旨在推进针对心脏代谢性疾病和罕见病的创新基因药物（genetic medicine）的开发。 该合作将NanoVation Therapeutics的专有长循环脂质纳米粒子（lcLNP）RNA递送技术与诺和诺德在心脏代谢性疾病和罕见病研发及临床转化方面的专长相结合。 根据协议条款，诺和诺德与NanoVation将合作开发两项主要项目，利用碱基编辑技术治疗某些罕见遗传病，并在未来扩 …
NanoVation Therapeutics Announces Multi-Target Partnership …
Sep 18, 2024 · VANCOUVER, British Columbia — NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.
Enabling genetic medicines - NanoVation Therapeutics
News & Events With the emergence of gene therapies, we are at a crucial turning point in human history. In our lifetimes, we will see major diseases become treatable or curable thanks to this new therapeutic approach.